Biopharmaceutical company targeted by a short-seller report.
2 AI-extracted insights from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Not enough scored insights about Soleno Therapeutics in the last 30 days yet.
The 1 sources with the most insights about Soleno Therapeutics on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
A 'battleground' stock with a strong bear case (short report citing safety/IP concerns) and a strong bull case (key doctor support could generate $250M revenue).
A 'battleground' stock with a strong bear case (short report citing safety/IP concerns) and a strong bull case (key doctor support could generate $250M revenue).
Other assets that creators frequently mention in the same content as Soleno Therapeutics.
The most active sources covering Soleno Therapeutics (SLNO) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 2 AI-extracted insights about Soleno Therapeutics (SLNO) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Soleno Therapeutics (SLNO) most frequently also discuss CGEM, NEGG, IONQ, RDDT, PGEN. See the "Discussed alongside" section above for full asset pages.